EKR Therapeutics

Bedminster, United States Founded: 2005 • Age: 21 yrs Acquired By Cornerstone Therapeutics
Oncology supportive care and generic products are manufactured and commercialized.
Annual revenue - Latest available
Total funding $63.0M 3 rounds
Employees - Tracked headcount
Investors 7 Known backers
Products - Services tracked
Competitors - Brand Intelligence

About EKR Therapeutics

EKR Therapeutics is a company based in Bedminster (United States) founded in 2005 by Cathy Kerzner and Richard DeSimone was acquired by Cornerstone Therapeutics in May 2012. EKR Therapeutics has raised $63 million across 3 funding rounds from investors including Cornerstone Therapeutics, GE Healthcare Equipment Finance and Turmeric Acquisition Corp.

  • Headquarter Bedminster, United States
  • Founders Cathy Kerzner, Richard DeSimone
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $63 M (USD)

    in 3 rounds

  • Latest Funding Round
    $50 M (USD), Series C

    Mar 10, 2008

  • Investors
  • Employee Count
    Not available
  • Acquired by
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of EKR Therapeutics

EKR Therapeutics has successfully raised a total of $63M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $50 million completed in March 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in EKR Therapeutics

EKR Therapeutics has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Cornerstone Therapeutics, GE Healthcare Equipment Finance and Turmeric Acquisition Corp.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Private equity firm investing in technology and healthcare businesses for growth capital.
Locked Locked Locked
Investment firm focusing on lower-middle market growth, healthcare, and various strategies.
Locked Locked Locked
-
Locked Locked Locked
Premium access

Investor details for EKR Therapeutics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by EKR Therapeutics

Investments
Premium access

Investment portfolio details for EKR Therapeutics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - EKR Therapeutics

Premium access

Detailed financials for EKR Therapeutics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Ekr Therapeutics Comparisons

EKR Therapeutics Primary company
Description
Oncology supportive care and generic products are manufactur...
Location
Bedminster, United States
Founded Year
2005
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for EKR Therapeutics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of EKR Therapeutics

Premium access

Detailed competitors of EKR Therapeutics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Ekr Therapeutics

Premium access

Complete news archive for EKR Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about EKR Therapeutics

EKR Therapeutics was founded in 2005 and raised its 1st funding round 2 years after it was founded.

EKR Therapeutics is headquartered in Bedminster, United States. It is registered at Bedminster, New Jersey, United States.

John Bailye is the current CEO of EKR Therapeutics.

EKR Therapeutics is a funded company, having raised a total of $63M across 3 funding rounds to date.

EKR Therapeutics was founded in 2005 and is located in Bedminster, United States. Operations in the specialty pharmaceutical sector involve the acquisition, development, and commercialization of prescription products focused on oncology supportive care. Therapeutic areas addressed include oral mucositis, stomatitis, dry mouth, nutritional support, cachexia, skin reactions, bone marrow depression, bone complications, pain management, nausea, vomiting, and diarrhea.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available